These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7508268)

  • 61. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
    Abu Ajaj K; Graeser R; Kratz F
    Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release.
    Pan YJ; Chen YY; Wang DR; Wei C; Guo J; Lu DR; Chu CC; Wang CC
    Biomaterials; 2012 Sep; 33(27):6570-9. PubMed ID: 22704845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sulfhydryl site-specific cross-linking and labeling of monoclonal antibodies by a fluorescent equilibrium transfer alkylation cross-link reagent.
    del Rosario RB; Wahl RL; Brocchini SJ; Lawton RG; Smith RH
    Bioconjug Chem; 1990; 1(1):51-9. PubMed ID: 2128870
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
    Yang HM; Reisfeld RA
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1189-93. PubMed ID: 3422487
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability.
    Kolodych S; Koniev O; Baatarkhuu Z; Bonnefoy JY; Debaene F; Cianférani S; Van Dorsselaer A; Wagner A
    Bioconjug Chem; 2015 Feb; 26(2):197-200. PubMed ID: 25614935
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma.
    Yeh MY; Roffler SR; Yu MH
    Int J Cancer; 1992 May; 51(2):274-82. PubMed ID: 1568795
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
    Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.
    Lyon RP; Meyer DL; Setter JR; Senter PD
    Methods Enzymol; 2012; 502():123-38. PubMed ID: 22208984
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An amino acid-based heterofunctional cross-linking reagent.
    Lelle M; Peneva K
    Amino Acids; 2014 May; 46(5):1243-51. PubMed ID: 24504931
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.
    Weber C; Reiss S; Langer K
    Int J Pharm; 2000 Dec; 211(1-2):67-78. PubMed ID: 11137340
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Analysis of monoclonal antibody chimeric BR96-doxorubicin immunoconjugate by sodium dodecyl sulfate-capillary gel electrophoresis with ultraviolet and laser-induced fluorescence detection.
    Liu J; Abid S; Lee MS
    Anal Biochem; 1995 Aug; 229(2):221-8. PubMed ID: 7485976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
    Tolcher AW; Sugarman S; Gelmon KA; Cohen R; Saleh M; Isaacs C; Young L; Healey D; Onetto N; Slichenmyer W
    J Clin Oncol; 1999 Feb; 17(2):478-84. PubMed ID: 10080588
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Protein conjugates of defined structure: synthesis and use of a new carrier molecule.
    Vilaseca LA; Rose K; Werlen R; Meunier A; Offord RE; Nichols CL; Scott WL
    Bioconjug Chem; 1993; 4(6):515-20. PubMed ID: 8305521
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Toxin-targeted design for anticancer therapy. I: Synthesis and biological evaluation of new thioimidate heterobifunctional reagents.
    Delprino L; Giacomotti M; Dosio F; Brusa P; Ceruti M; Grosa G; Cattel L
    J Pharm Sci; 1993 May; 82(5):506-12. PubMed ID: 8360828
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Release, partitioning, and conjugation stability of doxorubicin in polymer micelles determined by mechanistic modeling.
    Ponta A; Fugit KD; Anderson BD; Bae Y
    Pharm Res; 2015 May; 32(5):1752-63. PubMed ID: 25407546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.